Vivos Therapeutics, Inc.
VVOS
$2.57
-$0.06-2.28%
| Weiss Ratings | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.81 | |||
| Price History | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -30.73% | |||
| 30-Day Total Return | -22.36% | |||
| 60-Day Total Return | -41.19% | |||
| 90-Day Total Return | -9.19% | |||
| Year to Date Total Return | -39.53% | |||
| 1-Year Total Return | -24.08% | |||
| 2-Year Total Return | -69.76% | |||
| 3-Year Total Return | -95.10% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -58.12% | |||
| 52-Week Low % Change | 37.70% | |||
| Price | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.28 | |||
| 52-Week Low Price | $1.91 | |||
| 52-Week Low Price (Date) | May 30, 2024 | |||
| 52-Week High Price (Date) | Jan 17, 2025 | |||
| Valuation | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 15.49M | |||
| Enterprise Value | 10.74M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.62 | |||
| Earnings Per Share Growth | -58.20% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.19 | |||
| Price/Book (Q) | 1.64 | |||
| Enterprise Value/Revenue (TTM) | 0.74 | |||
| Price | $2.57 | |||
| Enterprise Value/EBITDA (TTM) | -0.90 | |||
| Enterprise Value/EBIT | -0.86 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 6.62M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 844 672 4357 | |||
| Address | 7921 Southpark Plaza Littleton, CO 80120 | |||
| Website | www.vivos.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -85.72% | |||
| Profit Margin | -86.19% | |||
| Management Effectiveness | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -60.88% | |||
| Return on Equity | -- | |||
| Income Statement | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 14.58M | |||
| Total Revenue (TTM) | 14.58M | |||
| Revenue Per Share | $2.20 | |||
| Gross Profit (TTM) | 9.01M | |||
| EBITDA (TTM) | -11.91M | |||
| EBIT (TTM) | -12.50M | |||
| Net Income (TTM) | -12.57M | |||
| Net Income Avl. to Common (TTM) | -12.57M | |||
| Total Revenue Growth (Q YOY) | 16.93% | |||
| Earnings Growth (Q YOY) | -24.99% | |||
| EPS Diluted (TTM) | -5.62 | |||
| EPS Diluted Growth (Q YOY) | 77.14% | |||
| Balance Sheet | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.31M | |||
| Cash Per Share (Q) | $0.95 | |||
| Total Current Assets (Q) | 7.40M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 7.67M | |||
| Current Ratio (Q) | 1.443 | |||
| Book Value Per Share (Q) | $1.61 | |||
| Total Assets (Q) | 15.35M | |||
| Total Current Liabilities (Q) | 5.13M | |||
| Total Debt (Q) | 1.64M | |||
| Total Liabilities (Q) | 7.68M | |||
| Total Common Equity (Q) | 7.67M | |||
| Cash Flow | VVOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -568.00K | |||
| Cash from Financing (TTM) | 18.39M | |||
| Net Change in Cash (TTM) | 5.32M | |||
| Levered Free Cash Flow (TTM) | -9.02M | |||
| Cash from Operations (TTM) | -12.50M | |||
